Deciphera Pharmaceuticals Inc (NASDAQ:DCPH)
| 60.95 BATS BZX Real-Time Price As of 12:18pm ET |  +1.60 / +2.69%Today’s Change | 33.10 Today|||52-Week Range 71.11 | -2.07% Year-to-Date |
Latest DCPH News | Press Releases
| Bristol-Myers' Acquisition of Bluebird Seems to Make Sense Oct 20 / GuruFocus News - Paid Partner Content |
Today’s Trading
| Previous close | 59.36 |
| Today’s open | 58.89 |
| Day’s range | 58.55 - 61.41 |
| Volume | 5,385 |
| Average volume (3 months) | 425,030 |
| Market cap | $3.3B |
Data as of 12:18pm ET, 10/21/2020
Growth & Valuation
| Earnings growth (last year) | -58.95% |
| Earnings growth (this year) | -16.56% |
| Earnings growth (next 5 years) | +21.00% |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | 106.73 |
| Price/Book | 5.56 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| KODKodiak Sciences Inc | -0.08 | -0.10% |
| MORMorphoSys AG | -0.37 | -1.38% |
| NKTRNektar Therapeutics | -0.47 | -2.74% |
| BLUEbluebird bio Inc | +0.36 | +0.66% |
Data as of 12:23pm ET, 10/21/2020
Financials
| Next reporting date | November 17, 2020 |
| EPS forecast (this quarter) | -$1.30 |
| Annual revenue (last year) | $25.0M |
| Annual profit (last year) | -$192.3M |
| Net profit margin | -769.02% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Waltham, Massachusetts |
Forecasts
